FrancophonIA/ELRC3.0 huggingface dataset:
English: Therefore, the CHMP's view was that, as for Seretide Diskus, the benefit outweighs the identified risk.
Estonian: Seetõttu on inimravimite komitee arvamusel, et nagu ka Seretide Diskuse korral, ületab ravimi kasulikkuse sellega kaasnevad riskid.
English: Since Airexar Spiromax is only available in one high strength (containing 50 micrograms of salmeterol and 500 micrograms of fluticasone propionate), should a lower strength become appropriate, patients should be switched to an alternative combination of salmeterol and fluticasone propionate containing a lower
Estonian: Et Airexar Spiromaxi turustatakse ainult ühe suureannuselise ravimvormina (sisaldab 50 µg salmeterooli ja 500 µg flutikasoonpropionaati), siis juhul, kui väiksem annus sobib, tuleb patsient üle viia flutikasoonpropionaadi väiksemat annust sisaldavale teisele salmeterooli ja flutikasoonpropionaadi
English: In asthma, Airexar Spiromax can be used in patients whose disease is not adequately controlled despite treatment with a combination of a beta-2 agonist and a lower dose of inhaled corticosteroid, or those whose asthma is already controlled with a long-acting beta-2 agonist and a high-dose of inhaled
Estonian: Astma ravis tohib Airexar Spiromaxi kasutada patsientidel, kelle haigus ei ole piisavalt ohjatud vaatamata ravile beeta-2-agonisti ja väiksemas annuses inhaleeritava kortikosteroidi kombinatsiooniga või kelle astma on juba ohjatud pikatoimelise beeta-2-agonisti ja suures annuses inhaleeritava kortikosteroidi kombinatsiooniga.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Airexar Spiromax have been included in the summary of product characteristics and the package leaflet.
Estonian: Airexar Spiromaxi ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: It contains the active substances salmeterol (a so-called long-acting beta-2 agonist) and fluticasone
Estonian: Ravim sisaldab toimeainetena salmeterooli (pikatoimeline beeta-2-agonist) ja flutikasoonpropionaati
English: What is Airexar Spiromax and what is it used for?
Estonian: Mis on Airexar Spiromax ja milleks seda kasutatakse?
English: For further information, see the package
Estonian: Üksikasjalik teave on pakendi infolehel.
English: Because Airexar Spiromax is a hybrid medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Estonian: Et Airexar Spiromax on hübriidravim ja võrdlusravimiga bioekvivalentne, peetakse tema kasulikkust ja riske samadeks mis võrdlusravimil.
English: It is not intended to provide practical advice on how to use Airexar Spiromax.
Estonian: Hindamisaruandes ei anta ravimi Airexar Spiromax kasutamise praktilisi nõuandeid.
English: This is a summary of the European public assessment report (EPAR) for Airexar Spiromax.
Estonian: See on ravimi Airexar Spiromax Euroopa avaliku hindamisaruande kokkuvõte.
English: The two active substances in Airexar Spiromax are well known and are present in several medicines used to treat asthma and COPD, either alone or in combination with other medicines.
Estonian: Airexar Spiromaxi mõlemad toimeained on hästi tuntud ning need sisalduvad mitmes ravimis, mida kasutatakse kas eraldi või kombinatsioonis muude ravimitega astma ja kroonilise obstruktiivse
English: Airexar Spiromax is a medicine used for the regular treatment of adults with severe asthma and for the relief of symptoms of chronic obstructive pulmonary disease (COPD, a long-term disease in which the airways and air sacs inside the lungs become damaged or blocked, leading to difficulty in breathing).
Estonian: Airexar Spiromax on ravim, mida kasutatakse raske astmaga täiskasvanud patsientidel püsiraviks ja kroonilise obstruktiivse kopsuhaiguse (krooniline haigus, mille korral bronhid ja kopsualveoolid on kahjustunud või ummistunud ja see põhjustab hingamisraskusi) sümptomite leevendamiseks.
English: Fluticasone propionate belongs to a group of anti-inflammatory medicines known as corticosteroids.
Estonian: Flutikasoonpropionaat kuulub põletikuvastaste ravimite kortikosteroidide rühma.
English: Other information about Airexar Spiromax
Estonian: Muu teave Airexar Spiromaxi kohta
English: However, Airexar Spiromax is available only as a single high strength, whereas the reference medicine is available in three strengths, the same high strength and two lower strengths.
Estonian: Airexar Spiromaxi turustatakse ainult ühe, suureannuselise ravimvormina, samas kui võrdlusravimit turustatakse kolme tugevusega (sama suureannuselise ja kahe väikseannuselise) ravimvormina.
English: Airexar Spiromax is a ‘hybrid medicine'.
Estonian: Airexar Spiromax on hübriidravim.
English: Airexar Spiromax is available as an inhalation powder in a portable inhaler device.
Estonian: Airexar Spiromaxi turustatakse inhalatsioonipulbrina kaasaskantavas inhalaatoris.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that Airexar Spiromax has been shown to have comparable quality and to be bioequivalent to Seretide Diskus.
Estonian: Inimravimite komitee otsustas, et on tõendatud Airexar Spiromaxi võrdväärne kvaliteet ja bioekvivalentsus ravimiga Seretide Diskus.
English: When it attaches to these receptors in the airways, it causes the muscles to relax, which keeps the airways open and helps with the patient's breathing.
Estonian: Selle toimel lihased lõõgastuvad, hoides hingamisteid avatuna, nii et patsiendil on
English: For more information about treatment with Airexar Spiromax, read the package leaflet (also part of the EPAR) or contact your
Estonian: Kui vajate ravimiga Airexar Spiromax toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: Salmeterol is a long-acting beta-2 agonist.
Estonian: Salmeterool on pikatoimeline beeta-2-agonist, mis seondub hingamisteede lihastes olevate beeta-2retseptoritega.
English: Studies in people have been limited to tests to determine that Airexar Spiromax is bioequivalent to the reference medicine, Seretide Diskus.
Estonian: Patsiendiuuringud piirdusid uuringutega, milles näidati ravimi Airexar Spiromax bioekvivalentsust võrdlusravimiga Seretide Diskus.
English: In COPD, Airexar Spiromax is used in adults who have had exacerbations (flare-ups) of the disease in the past and have significant symptoms despite regular treatment.
Estonian: Kroonilise obstruktiivse kopsuhaiguse ravis kasutatakse Airexar Spiromaxi täiskasvanud patsientidel, kellel regulaarsele ravile vaatamata esineb haiguse ägenemisi ja olulisi sümptomeid.
English: For practical information about using Airexar Spiromax, patients should read the package leaflet or
Estonian: Kui vajate ravimi Airexar Spiromax kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: How is Airexar Spiromax used?
Estonian: Kuidas Airexar Spiromax toimib?
English: How has Airexar Spiromax been studied?
Estonian: Kuidas Airexar Spiromaxi uuriti?
English: As Airexar Spiromax is only available in one high strength, its use in asthma has been restricted to
Estonian: Et Airexar Spiromaxi turustatakse ainult ühe suureannuselise ravimvormina, tohib seda ravimit astmapatsientidel kasutada ainult raskekujulise haiguse korral.
English: Airexar Spiromax can only be obtained with a prescription.
Estonian: Airexar Spiromax on retseptiravim.
English: What are the benefits and risks of Airexar Spiromax?
Estonian: Milles seisneb Airexar Spiromaxi kasulikkus ja mis riskid ravimiga
English: Page 2/2
Estonian: Lk 2/2
English: 2 February 2016 EMA/283374/2014
Estonian: veebruar 2016 EMA/283374/2014
English: Herbal medicine: summary for the public
Estonian: Taimne ravim: kokkuvõte üldsusele
English: These combinations are not covered in this summary.
Estonian: Käesolevas kokkuvõttes neid segusid ei käsitleta.
English: This means that, although there is insufficient evidence from clinical trials, the effectiveness of these herbal medicines is plausible and there is evidence that they have been used safely in this way for at least 30 years (including at least 15 years within the EU).
Estonian: See tähendab, et kuigi puuduvad kliinilistest uuringutest saadud piisavad tõendid, on tõenäoline, et need taimsed ravimid on efektiivsed, ja on tõendeid, et neid on sel viisil ohutult kasutatud vähemalt 30 aastat (sh vähemalt 15 aastat Euroopa Liidus).
English: Moreover, the intended use does not require medical supervision.
Estonian: Sellisel kavandatud kasutamisel ei ole vaja meditsiinilist järelevalvet.
English: A doctor or a qualified healthcare practitioner should be
Estonian: arsti või pädeva tervishoiutöötaja poole.
English: Although a possible effect on tiredness and weakness was observed, shortcomings in the design of the studies prevented any firm conclusions being drawn.
Estonian: Kuigi täheldati võimalikku mõju väsimusele ja nõrkusele, ilmnesid puudused nende uuringute ülesehituses.
English: 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom consulted if the symptoms continue for more than 2 weeks of treatment.
Estonian: 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom2.
English: Eleutherococcus root should only be used in adults and adolescents over the age of 12 years and should not be taken for more than 2 months.
Estonian: Eleuterokokijuurt sisaldavaid ravimeid tohivad kasutada üksnes täiskasvanud ja üle 12-aastased lapsed ning neid ei tohi võtta kauem kui 2 kuud.
English: Eleutherococcus root EMA/283374/2014
Estonian: Eleuterokokijuur EMA/283374/2014
English: Further information on the risks associated with eleutherococcus root medicines, including the appropriate precautions for their safe use, can be found in the monograph under the tab ‘All documents' on the Agency's website: ema.europa.eu/Find medicine/Herbal medicines for human use.
Estonian: Lisateave nende eleuterokokijuurt sisaldavate ravimitega kaasnevate riskide, sh nende ohutu kasutamise ettevaatusabinõude kohta, on taimse aine monograafias Euroopa Ravimiameti veebilehe jaotises „All documents“: ema.europa.eu/Find medicine/Herbal medicines for human use.
English: For detailed information on the studies assessed by the HMPC, see the HMPC assessment report.
Estonian: Üksikasjalik teave taimsete ravimite komitee hinnatud uuringute kohta on komitee hindamisaruandes.
English: The HMPC concluded that, on the basis of its long-standing use, eleutherococcus root can be used for the relief of symptoms of asthenia (abnormal loss of strength and energy) such as tiredness and weakness.
Estonian: Taimsete ravimite komitee järeldas, et lähtudes pikaajalisest kasutamisest tohib eleuterokokijuurt kasutada asteenia (ebatavaline jõuetus ja energiapuudus) sümptomite, näiteks väsimuse ja nõrkuse leevendamiseks.
English: In some cases the solvent is evaporated to obtain a dry extract.
Estonian: Mõnel juhul lahusti aurustatakse, et järele jääks kuivekstrakt.
English: Further information on the HMPC assessment of eleutherococcus root medicines, including details of the Committee's conclusions, can be found under the tab ‘All documents' on the Agency's website: ema.europa.eu/Find medicine/Herbal medicines for human use.
Estonian: Lisateave eleuterokokijuurt sisaldavate ravimite hindamise kohta, sh komitee kokkuvõtte üksikasjalik kirjeldus, on Euroopa Ravimiameti veebilehe jaotises „All documents“: ema.europa.eu/Find medicine/Herbal medicines for human use.
English: They are also obtained by using a technique to extract compounds from plant material by dissolving them in a solvent (such as ethanol or water) to form a liquid extract or tincture (an alcoholic extract).
Estonian: Neid saadakse ka taimeosade asetamisel lahustisse (nt etanooli või vette), et ekstraheerida ühendid ja saada vedelekstrakt või tinktuur (teatud alkoholekstrakt).
English: Detailed instructions on how to take eleutherococcus root medicines and who can use them can be found in the package leaflet that comes with the medicine.
Estonian: Üksikasjalik teave, kuidas võtta eleuterokokijuurt sisaldavaid ravimeid ja kes neid tohib kasutada, on ravimi pakendi infolehel.
English: Any applications for the licensing of medicines containing eleutherococcus root have to be submitted to the national authorities responsible for medicinal products, which will assess the application for the herbal medicine and take into account the scientific conclusions of the HMPC.
Estonian: Eleuterokokijuurt sisaldavate ravimite müügiloa taotlus tuleb esitada riiklikule ravimiametile, mis hindab taimsete ravimite müügiloa taotlust, võttes arvesse taimsete ravimite komitee teaduslikke järeldusi.
English: The HMPC conclusions on the use of eleutherococcus root medicines for relieving symptoms of asthenia are based on their ‘traditional use' in this condition.
Estonian: Taimsete ravimite komitee järeldused eleuterokokijuurt sisaldavate ravimite kasutamise kohta asteenia sümptomite leevendamiseks põhinevad nende traditsioonilisel kasutusel selle seisundi korral.
English: The HMPC conclusions are taken into account by EU Member States when evaluating applications for the licensing of herbal medicines containing eleutherococcus root.
Estonian: ELi liikmesriigid võtavad taimsete ravimite komitee järeldusi arvesse, kui nad hindavad eleuterokokijuurt sisaldavate taimsete ravimite müügilubade taotlusi.
English: Information on the use and licensing of eleutherococcus root medicines in EU Member States should be obtained from the relevant national authorities.
Estonian: ELi liikmesriikides saab eleuterokokijuurt sisaldavate ravimite kasutamise ja müügilubade teavet asjakohastelt riiklikelt ravimiametitelt.
English: This summary is not intended to provide practical advice on how to use medicines containing eleutherococcus root.
Estonian: Kokkuvõttes ei anta eleuterokokijuurt sisaldavate ravimite kasutamise praktilisi nõuandeid.
English: This is a summary of the scientific conclusions reached by the Committee on Herbal Medicinal Products (HMPC) on the medicinal uses of eleutherococcus root.
Estonian: See on taimsete ravimite komitee teaduslike järelduste kokkuvõte, mis käsitleb eleuterokokijuure meditsiinilisi kasutusviise.
English: Insomnia, irritability, tachycardia (rapid heartbeat) and headaches have been reported as side effects with eleutherococcus root medicines, although their frequency is not known.
Estonian: Eleuterokokijuurt sisaldavate ravimite kohta teatatud kõrvaltoimed on unetus, ärritatavus, tahhükardia (kiirenenud südametegevus) ja peavalu, kuid nende esinemissagedus ei ole teada.
English: Herbal medicines containing eleutherococcus root are usually available as herbal teas to be drunk, or in solid or liquid forms to be taken by mouth.
Estonian: Eleuterokokijuurt sisaldavad taimseid ravimeid turustatakse tavaliselt joodava taimeteena ja suukaudse tahke aine või vedelikuna.
English: For more information about treatment with eleutherococcus root medicines, read the package leaflet that comes with the medicine or contact your doctor or pharmacist.
Estonian: Kui vajate eleuterokokijuurt sisaldavate ravimitega toimuva ravi kohta lisateavet, lugege ravimi pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: What are the HMPC conclusions on its medicinal uses?
Estonian: Mis on taimsete ravimite komitee järeldused eleuterokokijuure meditsiiniliste kasutusalade kohta?
English: For practical information about using eleutherococcus root medicines, patients should read the package leaflet that comes with the medicine or contact their doctor or pharmacist.
Estonian: Kui vajate eleuterokokijuurt sisaldavate ravimite kasutamise kohta praktilisi nõuandeid, lugege ravimi pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: Eleutherococcus root can also be found in combination with other herbal substances in some herbal medicines.
Estonian: Mõnes taimses ravimis võib esineda eleuterokokijuure valmistisi ka kombinatsioonis teiste taimsete ainetega.
English: Eleutherococcus root is the common name for the root of the plant Eleutherococcus senticosus (Rupr.
Estonian: Eleuterokokijuur on taime Eleutherococcus senticosus (Rupr.
English: What are the risks associated with eleutherococcus root medicines?
Estonian: Mis riskid eleuterokokijuurt sisaldavate ravimitega kaasnevad?
English: Therefore, the HMPC conclusions on the use of eleutherococcus root medicines are based on their long-standing use.
Estonian: Seetõttu põhineb taimsete ravimite komitee järeldus eleuterokokijuurt sisaldavate ravimite kasutamise kohta nende pikaajalisel kasutamisel.
English: What evidence supports the use of eleutherococcus root medicines?
Estonian: Mis tõendid toetavad eleuterokokijuurt sisaldavate ravimite kasutamist?
English: In its assessment, the HMPC also considered numerous clinical studies with eleutherococcus root.
Estonian: Taimsete ravimite komitee uuris hinnangu andmisel ka mitmeid eleuterokokijuure kliinilisi uuringuid.
English: Other information about eleutherococcus root medicines
Estonian: Muu teave eleuterokokijuurt sisaldavate ravimite kohta
English: Eleutherococcus root preparations are obtained by drying and comminuting (reducing into tiny pieces) or powdering the root.
Estonian: Eleuterokokijuure valmistisi saadakse juure kuivatamisel ja peenestamisel või pulbristamisel.
English: How are eleutherococcus root medicines approved in the EU?
Estonian: Kuidas antakse Euroopa Liidus eleuterokokijuurt sisaldavate ravimite müügiluba?
English: This summary was last updated in 04-2009.
Estonian: Kokkuvõtte viimane uuendus: 04-2009.
English: The medicine can only be obtained with a prescription.
Estonian: Seda ravimit saab üksnes retsepti alusel.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the studies performed, to reach their recommendations on how to use the medicine.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas tehtud uuringuid, et koostada ravimi kasutamise soovitused.
English: This document is a summary of the European Public Assessment Report (EPAR).
Estonian: Käesolev dokument on Euroopa avaliku hindamisaruande kokkuvõte.
English: Its use during the first three months of pregnancy is not recommended.
Estonian: Ravimit ei soovitata kasutada raseduse esimese kolme kuu ajal.
English: The full list of these medicines is given in the Package Leaflet.
Estonian: Selliste ravimite täielik loetelu on pakendi infolehel.
English: This medicine is the same as Karvezide, which is already authorised in the European Union (EU).
Estonian: See ravim on samane Karvezidega, millel juba on Euroopa Liidus müügiluba.
English: If you need more information about your medical condition or your treatment, read the Package Leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate oma haigusseisundi või ravi kohta asjakohast lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: If you want more information on the basis of the CHMP recommendations, read the Scientific Discussion (also part of the EPAR).
Estonian: Kui soovite lisateavet inimravimite komitee soovituste aluse kohta, lugege palun teadusliku arutelu kokkuvõtet (samuti Euroopa avaliku hindamisaruande osa).
English: By blocking the receptors to which angiotensin II normally attaches, irbesartan stops the hormone having an effect, allowing the blood vessels to widen.
Estonian: Blokeerides retseptorid, millele angiotensiin II tavaliselt kinnitub, peatab irbesartaan hormooni toime ja soodustab veresoonte laienemist.
English: The combination of the two active substances has an additive effect, reducing the blood pressure more than either medicine alone.
Estonian: Nende kahe toimeaine kombinatsioonil on aditiivne toime: kombinatsioon alandab vererõhku rohkem kui kumbki ravim eraldi.
English: The main measure of effectiveness was the reduction in diastolic blood pressure (the blood pressure measured between two heartbeats).
Estonian: Efektiivsuse põhinäitaja oli diastoolse vererõhu (vererõhk kahe südamelöögi vahel ehk nn alumine vererõhk) alanemine.
English: ‘Essential' means that the hypertension has no obvious cause.
Estonian: Essentsiaalne tähendab, et kõrgvererõhutõbe ei põhjusta ükski teine haigus.
English: The European Commission granted a marketing authorisation valid throughout the EU for Irbesartan Hydrochlorothiazide BMS to Bristol-Myers Squibb Pharma EEIG on 19 January 2007.
Estonian: Muu teave Irbesartan Hydrochlorothiazide BMSi kohta Euroopa Komisjon andis Irbesartan Hydrochlorothiazide BMSi müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, ettevõttele Bristol-Myers Squibb Pharma EEIG 19. jaanuaril 2007.
English: Irbesartan on its own has been approved in the EU since 1997 under the names Karvea and Aprovel.
Estonian: Ibesartaan eraldi on olnud Euroopa Liidus ravimitena Karvea ja Aprovel heaks kiidetud alates 1997. aastast.
English: It is available as oval tablets (peach: 150 mg or 300 mg irbesartan and 12.5 mg hydrochlorothiazide; pink: 300 mg irbesartan and 25 mg hydrochlorothiazide).
Estonian: Seda turustatakse ovaalsete tablettidena (kahvatuoranžid 150 mg või 300 mg irbesartaani ja 12,5 mg hüdroklorotiasiidi; roosad 300 mg irbesartaani ja 25 mg hüdroklorotiasiidi).
English: Irbesartan Hydrochlorothiazide BMS is taken by mouth, with or without food.
Estonian: Irbesartan Hydrochlorothiazide BMSi manustatakse suu kaudu, koos toiduga või ilma.
English: The most common side effects with Irbesartan Hydrochlorothiazide BMS (seen in between 1 and 10 patients in 100) are dizziness, nausea (feeling sick) or vomiting, abnormal urination, fatigue (tiredness), and increases in blood urea nitrogen (BUN, a breakdown product of protein), creatinine (a breakdown product of muscle) and creatine kinase (an enzyme found in muscle).
Estonian: Irbesartan Hydrochlorothiazide BMSi kõige sagedamad kõrvalnähud (esinenud ühel kuni kümnel patsiendil sajast) on peapööritus, iiveldus või oksendamine, urineerimishäired, väsimus, vere uurealämmastiku (BUN, valgu lagunemissaadus), kreatiniini (lihasest vabanev aine) ja kreatiinkinaasi (lihastes leiduv ensüüm) sisalduse suurenemine.
English: Increasing the dose to 300 mg irbesartan and 25 mg hydrochlorothiazide may give a further decrease in blood pressure.
Estonian: Annuse suurendamisel koguseni 300 mg irbesartaani ja 25 mg hüdroklorotiasiidi võib vererõhk alaneda veelgi.
English: Irbesartan is an ‘angiotensin II receptor antagonist', which means that it blocks the action of a hormone in the body called angiotensin II.
Estonian: Irbesartaan on angiotensiin II retseptori antagonist, mis blokeerib organismi hormooni angiotensiin II toime.
English: It works by increasing urine output, reducing the amount of fluid in the blood and lowering the blood pressure.
Estonian: Diureetikum suurendab uriinieritust, vähendades vedeliku hulka veres ja langetades vererõhku.
English: Angiotensin II is a powerful vasoconstrictor (a substance that narrows blood vessels).
Estonian: Angiotensiin II on tugev vasokonstriktor (ahendab veresooni).
English: It must not be used in women who are more than three months pregnant.
Estonian: Ravimit ei tohi kasutada rasedatel pärast esimest kolme raseduskuud.
English: The company that makes Karvezide has agreed that its scientific data can be used for Irbesartan Hydrochlorothiazide BMS.
Estonian: Karvezide tootja on andnud nõusoleku, et tema teaduslikke andmeid võib kasutada ka Irbesartan Hydrochlorothiazide BMSi toetuseks.
English: Hydrochlorothiazide is a diuretic, which is another type of treatment for hypertension.
Estonian: Hüdroklorotiasiid on diureetikum, mis on hüpertensiooni teist tüüpi ravim.
English: EUROPEAN PUBLIC ASSESSMENT REPORT (EPAR) IRBESARTAN HYDROCHLOROTHIAZIDE BMS EPAR summary for the public
Estonian: EUROOPA AVALIK HINDAMISARUANNE IRBESARTAN HYDROCHLOROTHIAZIDE BMS Kokkuvõte üldsusele
English: Doses higher than 300 mg irbesartan and 25 mg hydrochlorothiazide once a day are not recommended.
Estonian: Üle 300 mg irbesartaani ja 25 mg hüdroklorotiasiidi annuseid üks kord ööpäevas ei soovitata.